Therapy-related acute myeloid leukemia following radioactive iodine treatment for thyroid cancer

Abstract

T-AML following radioiodine therapy for thyroid cancer appears to have a shorter latency period than other types of t-AML, which is an important consideration for post-therapy surveillance. Reporting of cases and outcomes will help provide data for further research. Identifying biomarkers that help risk-stratify patients prior to therapy and specific genetic-guided therapies may help improve outcomes.

Crystal engineering of coordination-polymer-based iodine adsorbents using a π-electron-rich polycarboxylate aryl ether ligand

“…[1][2][3][4][5][6][7] However, these isotopes are harmful to human health as they can be absorbed by the thyroid gland when inhaled, causing thyroid cancer, leukemia, and other diseases. [8][9][10] Because of this health concern, effective techniques must be developed for the controllable recovery and release of I 2 . So far, a few types of porous materials have been developed for capturing I 2 , such as chalcogenide aerogels, functionalized clays, and silver-based porous zeolitic materials.…”

Acute Myeloid Leukemia after Low-Dose Radioiodine Therapy for Papillary Thyroid Carcinoma

“…In a 2016 review of 37 patient with t-AML the most common subtype noted was trans t(15;17), less commonly inv(16) type reported after RAI therapy [4,9].…”

“…Acute myeloid leukemia (AML) is characterized by a rapid increase in the number of immature white blood cells. In most cases with RAI therapy-induced leukemia reported in the literature it developed after higher cumulative doses of RAI therapy [4] (Table 1).…”

Interstitial Deletion of Chromosome 9q in Therapy-Related Acute Promyelocytic Leukemia with Pathognomonic t(15;17) in a Patient Exposed to Radioactive Iodine

“…A recent review of 37 cases of therapy related myeloid neoplasms following RAI therapy for thyroid cancer found a shorter latency period (1-4 years) in these patients when compared to those associated with alkylating agents and irradiation [9]. A short period of post-RAI treatment surveillance may be reasonable if a causative relationship is established between RAI exposure and development of myeloid neoplasms.…”

“…This translocation causes fusion of Retinoic Acid Receptor-alpha (RAR-alpha, RARa) gene on chromosome 17 and the Promyelocytic Leukemia (PML) gene on chromosome 15. Although several cases of t-APL have been identified, only six cases of t-APL have been reported after RAI therapy [4][5][6][7][8][9]. Deletion in…”